Wound stimulation by growth-arrested human keratinocytes and fibroblasts: HP802-247, a new-generation allogeneic tissue engineering product

Dermatology

Volumn 220, Issue 2, 2010, Pages 114-120

  Goedkoop, René ^a   Juliet, Rodney ^d   You, Percy Hou Kang ^e   Daroczy, Judit ^f   De Roos, Kees Peter ^g   Lijnen, Raf ^h   Rolland, Eric ^b   Hunziker, Thomas ^c  

^a Shogu Consulting   (Switzerland)

^b DFB Pharmaceuticals Inc   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d St Elisabeth Hospital Willemstad   (Netherlands Antilles)

^e Dr Horacio E Oduber Hospital   (Aruba)

^f Szent Istvan Hospital   (Hungary)

^g BERNHOVEN HOSPITAL   (Netherlands)

^h LAURENTIUS HOSPITAL   (Netherlands)

Author keywords

Fibroblasts; Growth factors; HP802 247; Keratinocytes; Wound healing

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; FIBRIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PLACEBO; VASCULOTROPIN;

AGED; ARTICLE; CELL GROWTH; CELL THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EDEMA; ERYTHEMA; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; KERATINOCYTE; LEG ULCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SAFETY; TISSUE ENGINEERING; TISSUE ENGINEERING PRODUCT; TREATMENT OUTCOME; WOUND CLOSURE; WOUND COMPLICATION; WOUND DISCHARGE;

AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; FEMALE; FIBROBLASTS; HUMANS; KERATINOCYTES; LEG INJURIES; MALE; MIDDLE AGED; SKIN ULCER; TISSUE ENGINEERING; VASCULAR ENDOTHELIAL GROWTH FACTORS; WOUND HEALING;

EID: 77949275244     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000277380     Document Type: Article

References (22)

1. Marston WA, Carlin RE, Passman MA, Keay BA: Healing rates and cost efficacy of outpatient compression treatment for leg ulcers associated with venous insufficiency. J Vasc Surg 1999;30:491-498.
2. Lin JW, Beusterien KM, Childs MB: Medical costs of treating venous stasis ulcers: evidence from a retrospective cohort study. Vasc Med 1999;4:1-7.
3. Hunziker T: Autologer kultivierter Hautersatz. Hautarzt 2004;55:1077-1085.
4. Lysaght MJ, Hazlehurst AL: Tissue engineering: the end of the beginning. Tissue Eng 2004;10:309-320.
5. Tausche A-K, Skaria M, Böhlen L, Liebold K, Hafner J, Friedlein H, Meurer M, Goedkoop RJ, Wollina U, Salomon D, Hunziker T: An autologous epidermal equivalent tissue-engineered from follicular outer root sheath keratinocytes is as effective as split-thickness skin autograft in recalcitrant vascular leg ulcers. Wound Repair Regen 2003;11:248-252.
6. Heng BC, Cao T, Liu H, Phan TT: Directing stem cells into the keratinocyte lineage in vitro. Exp Dermatol 2005;14:1-16.
7. Wu XZ: Origin of cancer stem cells: the role of self-renewal and differentiation. Ann Surg Oncol 2008;15:407-414. 8 Ehrenreich M, Ruszczak Z: Update on tissue-engineered biological dressings. Tissue Eng 2006;12:2407-2424. 9 Falanga V, Margolis D, Alverez O, et al: Rapid healing of venous ulcers and lack of clinical rejection with an allogenic cultured human skin equivalent. Arch Dermatol 1998;134:293-300.
8. Glatt PM: Advanced clinical practice: skin substitutes (abstract C68). Symposium on Advanced Wound Care, Las Vegas, 2001. 11 Singer AJ, Clark RAF: Mechanisms of disease: cutaneous wound healing. New Engl J Med 1999;341:738-746.
9. Goedkoop RJ, Hunziker T: HP802-247, a growth-arrested, allogeneic cell-based treatment for chronic venous leg ulcers. WHS Seattle 2003 (abstract 71). Wound Repair Regen 2003; 11:A19.
10. Tolnai S: A method for viable cell count. Methods Cell Sci 1975;1:37-38.
11. Fletcher A, Cullum N, Sheldon TA: A systemic review of compression treatment for venous ulcers. Br Med J 1997;315:576-580.
12. Eldor R, Raz I, Ben Yehuda A, Boulton AJ: New and experimental approaches to treatment of diabetic foot ulcers: a comprehensive review of emerging treatment strategies. Diabet Med 2004;21:1161-1173.
13. Nolte SV, Xu W, Rennekampff HO, Rodemann HP: Diversity of fibroblasts - a review on implications for skin tissue engineering. Cells Tissues Organs 2008;187:165-176.
14. Limat A, Hunziker T, Boillat C, Bayreuther K, Noser F: Post-mitotic human dermal fibroblasts efficiently support the growth of human follicular keratinocytes. J Invest Dermatol 1989;92:758-762.
15. Wong T, McGrath JA, Navsaria H: The role of fibroblasts in tissue engineering and regeneration. Br J Dermatol 2007;156:1149-1155.
16. Williams D: A European regulatory pathway for tissue engineering at last. Med Device Technol 2007;18:10-11.
17. Brévignon-Dodin L, Livesey F: Regulation of tissue-engineered products in the European Union: where are we heading? Regen Med 2006;1:709-714.
18. FDA points to consider in the characterization of cell lines used to produce biologicals. Rockville, FDA, 1993, July 12th.
19. ICH guidance Q5D: Derivation and characterization of cell substrates used for production of biotechnological/biological products. July 1997.
20. Dunn CJ, Goa KL: Fibrin sealant: a review of its use in surgery and endoscopy. Drugs 1999;58:863-886.
21. Kubo K, Kuroyanagi Y: A study of cytokines released from fibroblasts in cultured dermal substitute. Artif Organs 2005;29:845-849.
22. Harkin DG, Dawson RA, Upton Z: Optimized delivery of skin keratinocytes by aerosolization and suspension in fibrin tissue adhesive. Wound Repair Regen 2006;14:354-363.